StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
BHVNBearishAnalyst Ratingnews
High materiality7/10

BofA Downgrade to Underperform Pressures Biohaven, Target Reduced to $11

Jun 29, 2026, 8:41 AM EDT2 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Downgrade to Underperform with a $11 PT and immediate 5.2% pre-market decline indicate near-term downside risk; biotech names are sensitive to analyst shifts, often causing multi-day to weeks of volatility.

AI summary

What happened, with direct paths to the underlying reporting

Bank of America Securities downgraded Biohaven (BHVN) to Underperform and cut the target from $12 to $11. The stock dropped 5.2% to about $15 in pre-market trading, signaling near-term downside risk. If sentiment remains negative or catalysts disappoint, BHVN could test the low-teens in the coming sessions.

  • BofA Securities downgrades Biohaven to Underperform; price target trimmed to $11.
  • Biohaven shares fall 5.2% pre-market to $15 on the downgrade.
  • Nasdaq 100 futures rise >1%, setting a mixed market backdrop.
  • Near-term BHVN downside risk increases if the rating sticks or sentiment worsens.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event

BHVNDec 26, 2025, 12:51 PM EST

US Stocks Mixed; Biohaven Shares Fall

BHVN shares fell after a disappointing Phase 2 study results. The study did not meet primary endpoint for major depressive disorder. Other U.S. stocks traded mixed on the same day…

Read signal →